FDA
-
-
-
-
-
-
-
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
-
-
-
-
-
-
-
FDA approves Gilead's Hepcludex as first HDV treatment in U.S.
-
-
-
-
-
-
-
Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026
-
-
-
-
-
-
-
PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access
-
-
-
-
-
-
-
UBS Reiterates Buy Rating on Gilead Sciences (GILD) Following ACLX Acquisition Announcement
-
-
-
-
-
-
-
Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results
-
-
-
-
-
-
-
Gilead HIV drug combination meets primary goal in phase 3 trial
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

